• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Pain Management Treatment Markets


News provided by

Reportlinker

May 22, 2013, 03:05 ET

Share this article

Share this article


NEW YORK, May 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pain Management Treatment Markets
http://www.reportlinker.com/p01138845/Pain-Management-Treatment-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

Pain management describes a particular set of drugs, analgesics, which are specifically used as therapeutics to control pain in the clinic. As pain affects 1.5 billion people worldwide, these drugs are one of the major segments of the central nervous system (CNS) therapies market. This TriMark Publications report focuses on the role of pain management drugs in clinical use and in drug development for acute pain, chronic pain, neuropathic path and nociceptive pain.

The report discusses drug development and targeted therapeutics, as well as their use in clinical trials. New approaches meant to aid in development of drugs for therapeutic use are emphasized. The study also analyzes almost all of the major, specialty and emerging companies known to be marketing, manufacturing or developing pain management treatment products in the U.S. and worldwide. Additionally, this review provides detailed tables, charts and figures with past and projected sales data for the U.S., Europe and other geographic regions.

TABLE OF CONTENTS

1. Overview 6
1.1 Statement of Report 6
1.2 About this Report 6
1.3 Scope of the Report 6
1.4 Objectives 6
1.5 Methodology 7
1.6 Executive Summary 9

2. Introduction 15
2.1 Overview of Pain 15
2.1.1 Acute Pain 15
2.1.2 Chronic Pain 16
2.1.3 Neuropathic Pain 17
2.1.4 Nociceptive Pain 18
2.2 Current Treatment Approaches 23
2.3 Key Problems 26
2.3.1 Side Effects of Therapy 26
2.3.2 Abuse Issues 27
2.4 The Need for New Treatments 37

3. Market Overview 38
3.1 Introduction 38
3.2 Market Analysis 38
3.3 Therapeutic Class 38
3.3.1 Opioids 39
3.3.2 NSAIDs 42
3.3.3 Local Anesthetics 44
3.3.4 Antidepressants 45
3.3.5 Anticonvulsants 46
3.4 Geographical Analysis 46
3.4.1 U.S. 46
3.4.2 Europe 49
3.4.3 Japan 50
3.5 Key Players 51

4. Pipeline Analysis 52
4.1 Introduction 52
4.2 Pain 54
4.3 Neuropathic Pain 55
4.4 Novel Therapeutic Approaches 56
4.4.1 CGRP Antagonists 56
4.4.2 CB2 Agonists 59
4.4.3 Sodium Channel Modulators 61
4.4.4 Calcium Channel Modulators 63
4.4.5 NMDA Antagonists 64
4.4.6 P2x Receptors 65
4.4.7 Trp Channels 67
4.5 Unsuccessful Targets 69
4.5.1 TrpV1 blockers 70
4.5.2 FAAH Inhibitors 71
4.5.3 Other Targets 73
4.6 Novel Formulations 76
4.6.1 Novel Opioids 78
4.6.2 Extended Release Formulations 79
4.6.3 Transdermal Formulations 81
4.6.4 Other Routes 82
4.6.5 Drug Combinations 82
4.7 Overview 85

5. The Changing Competitive Landscape 86
5.1 Overview 86
5.2 The Exit of Major Companies 86
5.3 Major Pharma Players 87
5.3.1 Abbott (AbbVie) 87
5.3.2 Astellas 87
5.3.3 Eli Lilly 87
5.3.4 Johnson & Johnson 87
5.3.5 Novartis 88
5.3.6 Pfizer 88
5.4 Pain Specialty Companies 89
5.4.1 Cephalon (Teva) 89
5.4.2 Endo Pharmaceuticals 89
5.4.3 Grünenthal 89
5.4.4 Hospira 90
5.4.5 Purdue Pharma 90
5.4.6 Mallinckrodt 90
5.5 Emerging Biotechs 91
5.5.1 AcelRx 91
5.5.2 Acura Pharmaceuticals 91
5.5.3 Afferent Pharmaceuticals 92
5.5.4 Algiax Pharmaceuticals 92
5.5.5 Arcion Therapeutics 92
5.5.6 BioDelivery Sciences International 92
5.5.7 Cara Therapeutics 93
5.5.8 Convergence Pharmaceuticals 93
5.5.9 Cytogel Pharma 93
5.5.10 DURECT 93
5.5.11 Egalet a/s 94
5.5.12 iMed 94
5.5.13 KemPharm 94
5.5.14 NeurAxon 95
5.5.15 NeurogesX 95
5.5.16 Newron Pharmaceuticals 95
5.5.17 Nuvo Research 96
5.5.18 Pacira Pharmaceuticals 96
5.5.19 Pain Therapeutics 96
5.5.20 QRx Pharma 96
5.5.21 Relmada Therapeutics 97
5.5.22 Relevare Pharmaceuticals 97
5.5.23 Spinifex Pharma 97
5.5.24 Xenon Pharma 98
5.5.25 Xenoport 98
5.5.26 Zalicus 98
5.5.27 Zogenix 99

6. Market Outlook 100
6.1 Overview 100
6.2 Increased Demand 100
6.3 The Continued Impact of Generics 101
6.4 Key Patent Expirations 101
6.5 Key New Launches 103
6.5.1 2012 103
6.5.2 2013 104
6.5.3 2014 104
6.5.4 2015 105
6.6 Overall Assessment 105
6.7 Market Forecast 106
6.7.1 Opioids 106
6.7.2 Neuropathic Pain 107
6.7.3 Migraine 108
6.7.4 Fibromyalgia 108
6.8 Geographical Analysis 108
6.8.1 U.S. 108
6.8.2 Europe 109
6.8.3 Japan 110
6.9 Conclusions 110

7. Company Profiles 113

Glossary 132

Bibliography 134

INDEX OF TABLES

Table 2.1: Treatment Recommendations for Osteoarthritic Pain 17
Table 2.2: Competitive Landscape for Postoperative Pain Management 21
Table 2.3: A Suggested Stepwise Approach to Treating Neuropathic Pain 25
Table 2.4: EULAR Recommendations for Treating Fibromyalgia 25
Table 2.5: Remoxy Versus OxyContin OC 32
Table 3.1: Branded Opioid Formulations and their Estimated 2012 Sales 41
Table 3.2: The More Widely Used NSAIDs 43
Table 3.4: 2012 U.S. Sales of Branded Triptan Containing Products for Migraine
Pain 49
Table 4.1: NCEs in Advanced Clinical Development for the Treatment of Pain 57
Table 4.2: CGRP Antagonists in Development for the Treatment of Migraine 58
Table 4.3: Cannabinoid Receptor Agonists that are or have been in Development 59
Table 4.4: Sodium Channel Blockers in Development for Pain Indications 61
Table 4.5: Calcium Channel Blockers in Active Development for the Treatment of
Pain 63
Table 4.6: NMDA Antagonists in Development for the Treatment of Pain 65
Table 4.7: P2x Channel Blockers in Active Development for the Treatment of Pain
66
Table 4.8: Active TrpV3 and TrpV4 Modulator Programs 67
Table 4.9: TrpA1 Blockers Reported to be in Active Development 68
Table 4.10: TrpM Channel Blockers Reported to be in Active Development 69
Table 4.11: TrpV1 Blockers Identified for Development in the Treatment of Pain
70
Table 4.12: FAAH Inhibitors Being Developed for Pain Indications 72
Table 4.13: Novel Approaches to the Treatment of Pain 74
Table 4.14: Novel Opioid Formulations in Development for the Treatment of Pain
77
Table 4.15: Novel Combination Formulations in Development for the Treatment of
Pain 83
Table 6.1: Market Drivers for the Pain Management Therapeutics Market 100
Table 6.2: Market Impediments for the Pain Management Therapeutics Market 100
Table 6.3: Status of Potential New Treatments for Neuropathic Pain 107

INDEX OF FIGURES

Figure 2.1: The Diverse Forms of Neuropathic Pain 18
Figure 2.2: The WHO-Recommended Treatment Ladder for Pain 23
Figure 2.3: Approved Treatment Options for Neuropathic Pain 24
Figure 2.4: Opioid Abuse and Emergency Eepartment Visits in the U.S., 2004 to
2008 29
Figure 2.5: Trends in Drug Abuse-Related ED Visits Involving Hydrocodone and
Oxycodone, Coterminous U.S., 1994-2002 30
Figure 2.6: Opioid Plasma Concentration Versus Time, "Bolus Effect" 30
Figure 2.7: OxyContin Original (OC) and Reformulated (OP) 31
Figure 2.8: How Remoxy Hinders Potential Drug Abuse 32
Figure 2.9: The Effect of Corporate Changes on Remoxy and Pain Therapeutics 33
Figure 2.10: Tamper Proofing with the Embeda Formulation 34
Figure 2.11: How Embeda Works 34
Figure 3.1: The Pain Market 2012, Segmentation by Therapeutic Class 39
Figure 3.2: Breakdown of 2012 Opioid Sales by Drug 40
Figure 3.3: The Leading NSAIDs and their Market Share in 2012 44
Figure 3.4: U.S. Sales of Opioid Products in 2012 by Volume 47
Figure 3.5: The U.S. Neuropathic Pain Market in 2012 48
Figure 3.6: The U.S. Fibromyalgia Pain Market in 2012 49
Figure 3.7: The 2012 Pain Market, Segmentation by Company 51
Figure 4.1: Novel Approaches to the Treatment of Pain 53
Figure 4.2: Pfizer's NCEs in Development for Pain in October 2008 54
Figure 4.3: Potential Targets for Treating Neuropathic Pain 55
Figure 6.1: Anticipated New Product Launches 2012-2015 103
Figure 6.2: Forecast Segmentation of the Pain Market in 2018 106
Figure 6.3: Forecast Breakdown of U.S. Neuropathic Pain Market in 2018 109
Figure 6.4: Geographic Distribution of the Acute and Chronic Pain Market in 2018
111
Figure 6.5: Geographic Distribution of the Migraine Market in 2018 111
Figure 6.6: Geographic Distribution of the Fibromyalgia Market in 2018 112
Figure 6.7: Geographic Distribution of the Neuropathic Pain Market in 2018 112

To order this report:
:
Pain Management Treatment Markets


Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.